Advice
Following a full submission
paricalcitol capsules 1, 2 and 4 micrograms (Zemplar®) are not recommended for use within NHS Scotland for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease [CKD] Stages 3 and 4) patients and chronic renal failure (CKD Stage 5) patients on haemodialysis or peritoneal dialysis.
The benefits and adverse effects of paricalcitol capsules compared to other vitamin D analogues have not directly been assessed. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice91KB (PDF)
Medicine details
- Medicine name:
- paricalcitol capsules 1,2 and 4 micrograms (Zemplar)
- SMC ID:
- 478/08
- Indication:
- for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency chronic kidney disease
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 July 2008